Innoviva (INVA) Operating Expenses (2010 - 2026)
Innoviva posted quarterly Operating Expenses of $37.7 million for Q1 2026, up 18.16% year-on-year from $31.9 million in Q1 2025, and down 8.01% on a QoQ basis from $41.0 million in Q3 2025.
Innoviva (INVA) has 17 years of Operating Expenses data on file, last reported at $37.7 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 18.16% year-over-year to $37.7 million; the trailing twelve-month figure through Mar 2026 stood at $113.0 million (up 22.92% YoY), and the FY2025 full-year result was $143.9 million, up 11.27% from the prior year.
- Operating Expenses for Q1 2026 stood at $37.7 million, down from $41.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at $87.7 million in Q2 2022 and bottomed at -$219.2 million in Q3 2022.
- The 5-year median for Operating Expenses is $34.4 million (2025), against an average of $18.8 million.
- Peak annual rise in Operating Expenses reached 1956.38% in 2022, while the deepest fall reached 765.76% in 2022.
- A 5-year view of Operating Expenses shows it stood at -$219.2 million in 2022, then jumped by 91.47% to -$18.7 million in 2023, then surged by 259.26% to $29.8 million in 2024, then surged by 37.59% to $41.0 million in 2025, then declined by 8.01% to $37.7 million in 2026.
- The last three Operating Expenses figures came in at $37.7 million (Q1 2026), $41.0 million (Q3 2025), and $34.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 37.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.68 Mn |
| Sep 30, 2025 | 40.96 Mn |
| Jun 30, 2025 | 34.40 Mn |
| Mar 31, 2025 | 31.89 Mn |
| Sep 30, 2024 | 29.77 Mn |
| Jun 30, 2024 | 30.30 Mn |
| Mar 31, 2024 | 34.28 Mn |
| Sep 30, 2023 | -18.69 Mn |
| Jun 30, 2023 | 75.19 Mn |
| Mar 31, 2023 | 35.23 Mn |
| Sep 30, 2022 | -219.17 Mn |
| Jun 30, 2022 | 87.73 Mn |
| Mar 31, 2022 | 45.34 Mn |
| Sep 30, 2021 | -25.32 Mn |
| Jun 30, 2021 | 4.27 Mn |
| Mar 31, 2021 | 6.04 Mn |
| Dec 31, 2020 | -27.43 Mn |
| Sep 30, 2020 | 4.26 Mn |
| Jun 30, 2020 | 3.16 Mn |
| Mar 31, 2020 | 2.56 Mn |
| Dec 31, 2019 | 2.33 Mn |
| Sep 30, 2019 | 4.96 Mn |
| Jun 30, 2019 | 4.35 Mn |
| Mar 31, 2019 | 3.02 Mn |
| Dec 31, 2018 | 2.64 Mn |
| Sep 30, 2018 | 4.02 Mn |
| Jun 30, 2018 | 4.41 Mn |
| Mar 31, 2018 | 11.69 Mn |
| Dec 31, 2017 | 3.11 Mn |
| Sep 30, 2017 | 8.62 Mn |
| Jun 30, 2017 | 10.73 Mn |
| Mar 31, 2017 | 11.15 Mn |
| Dec 31, 2016 | 5.95 Mn |
| Sep 30, 2016 | 5.39 Mn |
| Jun 30, 2016 | 6.60 Mn |
| Mar 31, 2016 | 6.64 Mn |
| Dec 31, 2015 | 5.54 Mn |
| Sep 30, 2015 | 5.13 Mn |
| Jun 30, 2015 | 5.55 Mn |
| Mar 31, 2015 | 6.15 Mn |
| Dec 31, 2014 | 7.15 Mn |
| Sep 30, 2014 | 10.54 Mn |
| Jun 30, 2014 | 10.73 Mn |
| Mar 31, 2014 | 13.94 Mn |
| Dec 31, 2013 | 8.89 Mn |
| Sep 30, 2013 | 8.12 Mn |
| Jun 30, 2013 | 8.22 Mn |
| Mar 31, 2013 | 8.10 Mn |
| Dec 31, 2012 | -82.22 Mn |
| Sep 30, 2012 | 34.78 Mn |
| Jun 30, 2012 | 37.14 Mn |
| Mar 31, 2012 | 41.06 Mn |
| Dec 31, 2011 | 40.94 Mn |
| Sep 30, 2011 | 35.63 Mn |
| Jun 30, 2011 | 30.05 Mn |
| Mar 31, 2011 | 27.63 Mn |
| Dec 31, 2010 | 24.88 Mn |
| Sep 30, 2010 | 25.15 Mn |
| Jun 30, 2010 | 25.70 Mn |